OptiNose logo

OptiNoseNASDAQ: OPTN

Profile

Sector:

Healthcare

Country:

United States

IPO:

13 October 2017

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$104.04 M
-68%vs. 3y high
44%vs. sector
-vs. 3y high
-vs. sector
-155%vs. 3y high
8%vs. sector
-66%vs. 3y high
29%vs. sector

Price

regular market | Thu, 31 Oct 2024 20:00:00 GMT
$0.69-$0.07(-9.20%)

Dividend

No data over the past 3 years
$20.49 M$23.00 M
$20.49 M-$7.58 M

Analysts recommendations

Institutional Ownership

OPTN Latest News

Optinose Appoints Terry Kohler as Chief Financial Officer
globenewswire.com07 October 2024 Sentiment: POSITIVE

YARDLEY, Pa., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Terry Kohler as Chief Financial Officer.

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
globenewswire.com05 September 2024 Sentiment: POSITIVE

YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review publication of a paper titled, “EDS-FLU efficacy in patients with chronic rhinosinusitis with or without prior sinus surgery in ReOpen1 and ReOpen2 randomized controlled trials”1 in the International Forum of Allergy & Rhinology, the journal of the American Rhinologic Society.

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: NEUTRAL

OptiNose, Inc. (NASDAQ:OPTN ) Q2 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Paul Spence - Chief Commercial Officer Conference Call Participants Schuyler van den Broek - Piper Sandler Thomas Flaten - Lake Street Capital Markets Operator Hello, and welcome to the OptiNose Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
zacks.com08 August 2024 Sentiment: NEUTRAL

OptiNose (OPTN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript
seekingalpha.com17 May 2024 Sentiment: NEGATIVE

OptiNose, Inc. (NASDAQ: OPTN) will be holding its Q1 2024 Results Conference Call on May 15, 2024 at 10:00 AM ET. Company representatives include Jonathan Neely, VP of IR & Business Development, and Dr. Ramy Mahmoud, CEO. Conference call participants include analysts from Lake Street Capital Markets, Piper Sandler, Jefferies, and H.C. Wainwright. The operator begins the call by thanking participants for joining.

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
globenewswire.com17 May 2024 Sentiment: POSITIVE

Optinose (NASDAQ: OPTN), a pharmaceutical company specializing in patients cared for by ear, nose, and throat (ENT) and allergy specialists, revealed today that its management team will be giving a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research14 May 2024 Sentiment: POSITIVE

OptiNose (OPTN) reported a quarterly loss of $0.12 per share, slightly higher than the expected loss of $0.10 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.17 per share reported in the same quarter last year.

Optinose to Present at the Needham Virtual Healthcare Conference
GlobeNewsWire04 April 2024 Sentiment: POSITIVE

YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.

OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research07 March 2024 Sentiment: NEGATIVE

OptiNose (OPTN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
GlobeNewsWire29 February 2024 Sentiment: NEGATIVE

Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time

What type of business is OptiNose?

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

What sector is OptiNose in?

OptiNose is in the Healthcare sector

What industry is OptiNose in?

OptiNose is in the Drug Manufacturers - Specialty & Generic industry

What country is OptiNose from?

OptiNose is headquartered in United States

When did OptiNose go public?

OptiNose initial public offering (IPO) was on 13 October 2017

What is OptiNose website?

https://www.optinose.com

Is OptiNose in the S&P 500?

No, OptiNose is not included in the S&P 500 index

Is OptiNose in the NASDAQ 100?

No, OptiNose is not included in the NASDAQ 100 index

Is OptiNose in the Dow Jones?

No, OptiNose is not included in the Dow Jones index

When was OptiNose the previous earnings report?

No data

When does OptiNose earnings report?

The next expected earnings date for OptiNose is 08 November 2024